Randomized and double-blinded clinical trial of the safety and calcium kidney stone dissolving efficacy of Lapis judaicus

被引:14
作者
Faridi, Pouya [1 ,2 ]
Seradj, Hassan [3 ]
Mohammadi-Samani, Soliman [4 ]
Vossoughi, Mehrdad [5 ]
Mohagheghzadeh, Abdolali [1 ,2 ]
Roozbeh, Jamshid [6 ]
机构
[1] Shiraz Univ Med Sci, Sch Pharm, Dept Phytopharmaceut Tradit Pharm, Shiraz, Iran
[2] Shiraz Univ Med Sci, Pharmaceut Sci Res Ctr, Shiraz, Iran
[3] Shiraz Univ Med Sci, Sch Pharm, Dept Pharmacognosy, Shiraz, Iran
[4] Shiraz Univ Med Sci, Sch Pharm, Dept Pharmaceut, Shiraz, Iran
[5] Shiraz Univ Med Sci, Sch Dent, Dept Dent Publ Hlth, Shiraz, Iran
[6] Shiraz Univ Med Sci, Shiraz Nephrourol Res Ctr, Shiraz, Iran
关键词
Calcium oxalate; Chemolysis; Clinical trial; Kidney stone dissolving; Lapis judaicus; Traditional Iranian medicine; CALCULI; URINE; CRYSTALLIZATION; MANAGEMENT; MAGNESIUM; CHLORIDE; MODEL;
D O I
10.1016/j.jep.2014.08.003
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Kidney stones are one of the most common disorders of the urinary tract and cause a great deal of morbidity and economic loss. Because of the side effects and costs of current interventional procedures, researchers are interested in finding medicinal therapies. In this regard, some reports have focused on traditional medicines as a drug discovery resource. Iranian scholars in the medieval era recommended Lapis judaicus for the prevention and treatment of kidney stones. The present study assessed the efficacy and safety of Lapis judaicus on the size of calcium kidney stones and some related biochemical factors in blood and urine. Materials and methods: Sixty patients with kidney stone disease were included in this double-blind randomized clinical study. Thirty patients received 2 g of Lapis judaicus powder in hard capsules per day for 10 weeks, and another 30 patients received a placebo for the same period. Ultrasonography was performed on patients, and blood and urine samples were collected before and after the study to evaluate the efficacy and safety of Lapis judaicus in calcium kidney stone patients. Results: The size of the kidney stones was reduced significantly (p < 0.001) in the drug group. In 9 patients from the drug group, the stone was completely dissolved. Moreover, urine calcium concentration and specific gravity were reduced and urine magnesium was increased (p < 0.05). Lapis judaicus did not affect BUN, creatinine, ALT, or AST. Conclusion: Contrary to the placebo group, the size of kidney stones was reduced significantly in the treatment group after oral administration of Lapis judaicus. This preliminary study confirms traditional knowledge of the efficacy and safety of Lapis judaicus in kidney stone diseases and suggests a new method to treat calcium kidney stones. Further detailed in vitro and in vivo studies aimed at discovering the mechanism of action of Lapis judaicus and clinical studies involving a larger population of patients will be necessary to fully explain and confirm the results obtained in the present study. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:82 / 87
页数:6
相关论文
共 23 条
[1]  
Ahmed S., 2009, J HERBAL MED TOXICOL, V3, P47
[2]  
Ali S, 1984, BAZAAR DRUGS FOLK ME, P69
[3]  
Ashtiyani SC, 2010, IRAN J KIDNEY DIS, V4, P106
[4]  
BRUNDIG P, 1981, EUR UROL, V7, P97
[5]   Herbal Medicines in the Management of Urolithiasis: Alternative or Complementary? [J].
Butterweck, Veronika ;
Khan, Saeed R. .
PLANTA MEDICA, 2009, 75 (10) :1095-1103
[6]   Stopping the Stones [J].
Coe, Fredric L. ;
Asplin, John R. .
SCIENCE, 2010, 330 (6002) :325-326
[7]   Lapis Judaicus or the Jews' stone: the folklore of fossil echinoid spines [J].
Duffin, Christopher J. .
PROCEEDINGS OF THE GEOLOGISTS ASSOCIATION, 2006, 117 :265-275
[8]   Effect of Cystone® on urinary composition and stone formation over a one year period [J].
Erickson, S. B. ;
Vrtiska, T. J. ;
Lieske, J. C. .
PHYTOMEDICINE, 2011, 18 (10) :863-867
[9]  
Faridi P., 2013, PHARMACOGNOSY J, V5, P94
[10]  
Faridi P, 2012, IRAN J KIDNEY DIS, V6, P339